Compare Enveric Biosciences Inc (ENVB) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Fidelity National Information Servcs Inc — how do they compare? Enveric Biosciences Inc trades at $1.56 (market cap $6.20M), while Fidelity National Information Servcs Inc trades at $41.78 (market cap $22.05B). The key difference: Fidelity National Information Servcs Inc is far larger — about 3556.5× Enveric Biosciences Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | FIS | |
|---|---|---|
Market Cap | $6.20M | $22.05B |
Sector | Health | Technology |
52-Week High | $17.40 | $72.77 |
52-Week Low | $1.27 | $37.72 |
Enterprise Value | $1.30M | $42.56B |
Dividend Yield | — | 4.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.56, up 1.3% on the day, with a bullish technical signal from moving averages and strong analyst support (75% buy ratings). The company reported four consecutive quarterly earnings beats in 2025, including a positive EPS of $0.85 in Q4, while recent news highlights progress in preclinical studies for its non-hallucinogenic psychiatric drug candidate EB-003.
Despite operational losses and negative ROE/ROA, ENVB's consistent earnings surprises and advancing pipeline present speculative growth potential. Key risks include cash burn, clinical trial outcomes, and regulatory hurdles, requiring careful risk assessment by investors.
FIS trades at $42.51, down 0.61% today. The stock shows mixed signals with a bearish technical trend but strong fundamentals, including a low P/E of 6.57 and robust ROE of 22.33%. Recent Q2 2026 earnings beat expectations, driven by Banking Solutions growth, though full-year guidance was trimmed. Positive news includes global platform expansions in APAC and industry recognition for treasury software.
The outlook is cautiously optimistic. Attractive valuation and profitability metrics present an opportunity, but risks include execution challenges in Capital Markets and competitive pressures. Analyst consensus is strongly Buy with a $50.18 price target, suggesting significant upside potential from current levels if growth initiatives succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
